Barclays lowered the firm’s price target on Sotera Health (SHC) to $17 from $18 and keeps an Overweight rating on the shares. Sentiment remains very bearish on the life science tools group from a focus on National Institutes of Health funding cuts impacting demand, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.